Trials / Unknown
UnknownNCT02132988
Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer
An Open Labeled Phase II Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Mackay Memorial Hospital · Academic / Other
- Sex
- Female
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after cytoreductive surgery and platinum-based chemotherapy as initial treatment for primary disease or as salvage treatment for first relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | OPT-822/OPT-821 |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2017-11-01
- Completion
- 2018-11-01
- First posted
- 2014-05-07
- Last updated
- 2014-05-07
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02132988. Inclusion in this directory is not an endorsement.